ALK’s Grazax in five-year landmark asthma prevention trial in children sees … – The Pharma Letter (registration)

ALK's Grazax in five-year landmark asthma prevention trial in children sees
The Pharma Letter (registration)
Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced disappointing top-line results from the Grazax Asthma Prevention (GAP) trial with ALK's allergy immunotherapy tablet against grass pollen allergy. The GAP trial consisted of a …

View full post on asthma – Google News

ALK announces top-line results from the five-year landmark GRAZAX® Asthma … – GlobeNewswire (press release)

ALK announces top-line results from the five-year landmark GRAZAX® Asthma
GlobeNewswire (press release)
The trial did not show an effect in terms of time to first diagnosis of reversible impairment of lung function. The trial demonstrated that GRAZAX® treatment significantly reduced the proportion of children experiencing asthma symptoms or using asthma …
BRIEF-Alk Abello announces results from GRAZAX Asthma Prevention trial in childrenReuters
ALK announces top-line results from the five-year landmark GRAZAX(r) Asthma EconoTimes

all 6 news articles »

View full post on asthma – Google News

ALK announces top-line results from the five-year landmark GRAZAX(r) Asthma … – EconoTimes

ALK announces top-line results from the five-year landmark GRAZAX(r) Asthma
EconoTimes
In contrast, treatment with GRAZAX(r) had a positive effect on the children's asthma symptoms and use of asthma medication. The odds ratio (secondary endpoint) for experiencing asthma symptoms[1] or using asthma medication[2], at the end of the five

and more »

View full post on asthma – Google News